MedPath

AMG 701 Expanded Access Program

Registration Number
NCT05256446
Lead Sponsor
Amgen
Brief Summary

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria
Exclusion Criteria

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath